[Octreotide treatment of post surgical chylothorax]

Area of Science:

• Pediatric Cardiology
• Thoracic Surgery
• Medical Therapeutics

Background:

• Chylothorax is a rare but serious complication following pediatric cardiac surgery.
• Conservative management (low-fat diet, parenteral nutrition) is often insufficient for persistent cases.
• Surgical interventions like pleuroperitoneal drainage or thoracic duct ligation carry significant risks.

Observation:

• A 3-year-old girl with Down syndrome and an atrioventricular canal defect developed chylothorax post-Glenn procedure.
• Standard treatments failed to resolve the chylothorax, which was associated with a pulmonary-cava fistula.
• Intravenous octreotide administration led to the remission of chylothorax.

Findings:

• Continuous intravenous octreotide (1-2 mcg/kg/min) achieved remission.
• Subcutaneous octreotide (20 mcg/kg/day) allowed for dietary normalization without recurrence.
• The treatment was well-tolerated with minimal adverse effects.

Implications:

• Octreotide represents a promising therapeutic option for pediatric chylothorax refractory to conventional treatments.
• This case highlights the potential of pharmacologic intervention in managing complex postoperative complications.
• Further research is warranted to establish octreotide's efficacy and safety profile in a larger pediatric cohort.